[Breaking] Anterogen Submits FDA Protocol Amendment for U.S. Phase 2 Trial of DEB Treatment 'Allo-ASC-Sheet'
Anterogen announced that it has submitted a Protocol Amendment for the U.S. clinical trial of 'Allo-ASC-Sheet,' a treatment for Dystrophic Epidermolysis Bullosa (DEB), to the U.S. Food and Drug Administration (FDA). The date of the amendment approval request was September 16, 2026. This trial is a
![[Breaking] Anterogen Submits FDA Protocol Amendment for U.S. Phase 2 Trial of DEB Treatment 'Allo-ASC-Sheet'](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581419%2F479dac739b049517%2Foriginal.webp&w=1920&q=75)
Anterogen announced that it has submitted a Protocol Amendment for the U.S. clinical trial of 'Allo-ASC-Sheet,' a treatment for Dystrophic Epidermolysis Bullosa (DEB), to the U.S. Food and Drug Administration (FDA). The date of the amendment approval request was September 16, 2026.
This trial is a U.S. Phase 2 clinical study evaluating the efficacy and safety of 'Allo-ASC-Sheet' in DEB patients. It will be conducted in the United States, with approximately five clinical trial sites expected to participate, and the trial sites are listed as the United States and/or the Republic of Korea. The target number of subjects is six in total—three pediatric and three adult patients—and the trial period is approximately 25 months, from around 2026 to 2028.
▲ Clarification of Target Wound Selection and Evaluation Criteria Through this amendment, Anterogen has clarified the selection and evaluation criteria for the Target Wound and revised parts of the trial design and assessment methods to appropriately evaluate the wound characteristics of DEB patients and the therapeutic effect of the investigational product.
The key changes include: △ supplementing the selection criteria to account for the size and characteristics of target wounds; △ adjusting efficacy endpoints and evaluation methods; and △ accordingly revising parts of the trial procedures and related standards.
The primary endpoint is the proportion of individual target wounds meeting pre-defined criteria for wound area reduction five weeks after completion of the 12-week treatment period. The trial will be conducted in a double-blind, randomized manner.
▲ "Does not signify amendment approval or trial success" The company plans to proceed with the relevant regulatory procedures following the submission of the amendment to the FDA. However, it stated that the submission of this Protocol Amendment does not imply FDA approval of the amendment or the success of the clinical trial results.
During the FDA review process, additional data submissions or supplements may be required, as well as further changes to the trial protocol, and the amended protocol will be implemented after the necessary procedures with the relevant regulatory authorities and the Institutional Review Board (IRB) are completed.
The company also explained that the progress and results of the clinical trial may be changed or delayed depending on subject recruitment, the operational status of trial sites, regulatory review, and other circumstances.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



![[Featured Stocks] MLCC-related stocks fall across the board... Amotech plunges 17%, Samsung Electro-Mechanics drops below 800,000 won](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F10%2F618733%2F32ad1c6b0cafe51d%2Fvariants%2Fhero.webp&w=1920&q=75)